Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Wednesday's Bonus Content 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Date Posted: 2/24/2026. 
What You Need to Know - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
While many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks trading under $5 carry significant risk: many of these companies are unprofitable, and some generate little to no revenue. These are typically small-cap companies, a segment that has been beaten up in recent years. Even with the Russell 2000 showing some signs of recovery, that improvement hasn't been broad-based across the small-cap sector. That could change in 2026 if the economic outlook continues to improve, potentially drawing money back into speculative names. As with any market segment, though, quality matters. One way to filter for quality is to favor names with positive analyst sentiment. These three stocks fit that description. Each allows investors to start a sizable position with a modest outlay while still offering the potential for meaningful upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks are expected to be among the winners in 2026, though that hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% this year. Based in Singapore, Grab operates a super app that blends technology, e-commerce and fintech services. Part of the recent pullback stems from its proposed merger with Indonesian ride-share competitor Go To. The deal is not final and could face significant legislative changes in Indonesia that might limit the company's earnings potential there. Grab also missed the top line in its Q4 2025 earnings report. Still, revenue rose 19% year-over-year (YOY), and 2025 marked the company's first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains bullish. GRAB has a consensus price target of $6.47, about 54% above its current level. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector to balance risk and reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that fits the classic penny-stock definition. At the time of writing, it traded just above $0.60 per share. VXRT lacks heavy analyst coverage, but the sole analyst rating in the past 12 months is a Buy with a $2 price target. That limited coverage isn't uncommon for clinical-stage biotechs—Vaxart's candidates are still in clinical trials. The upside, however, is clear: the company is developing oral vaccines targeting influenza, norovirus and COVID-19. Beyond convenience and avoiding needles, Vaxart says its oral platform may induce a broader immune response and broader protection. Institutional ownership is only about 18%, but in terms of dollar volume, inflows outnumber outflows nearly 10:1, which is notable for such a small-cap, clinical-stage name. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but a longer view shows the stock up more than 66% over the last 12 months. That suggests the recent drop may be a pullback amid a market that's shunning companies not yet profitable. ThredUp operates an online consignment and thrift platform that has gained traction with Gen Z. In its most recent quarter, revenue rose 12.5% YOY. The company cites a GlobalData 2025 Market Survey forecasting the U.S. secondhand market's gross merchandise value to grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutions own roughly 89% of TDUP. Dollar buying has outpaced selling about 2:1, and buyer/seller counts are about 3:1. That said, short interest of around 17% can add near-term volatility. The consensus price target from six analysts is $12.50, which would represent roughly a 190%+ upside from the price at the time of writing.
| 
